Safety of Oral and Intravenous Iron

    Research output: Contribution to journalArticle

    2 Citations (Scopus)

    Abstract

    As the adverse effects of iron deficiency are better recognized, the use of oral and intravenous iron has increased dramatically. Oral iron is often poorly tolerated, with up to 70% or more of patients noting gastrointestinal issues; this may affect adherence to therapy. In addition, many patients will not respond to oral iron due to their underlying illness. Intravenous iron is being used more frequently to replete iron stores. True anaphylaxis is very rare, but complement-mediated infusion reactions may be seen in up to 1 in every 200 patients. Previous concerns about intravenous iron increasing the risk of infection or cardiovascular disease are unfounded.

    Original languageEnglish (US)
    Pages (from-to)8-12
    Number of pages5
    JournalActa Haematologica
    DOIs
    StatePublished - Jan 1 2019

    Fingerprint

    Iron
    Safety
    Anaphylaxis
    Cardiovascular Diseases
    Infection

    ASJC Scopus subject areas

    • Hematology

    Cite this

    Safety of Oral and Intravenous Iron. / Deloughery, Thomas.

    In: Acta Haematologica, 01.01.2019, p. 8-12.

    Research output: Contribution to journalArticle

    @article{89d8aec544534eeeafb9cf24e0a6d676,
    title = "Safety of Oral and Intravenous Iron",
    abstract = "As the adverse effects of iron deficiency are better recognized, the use of oral and intravenous iron has increased dramatically. Oral iron is often poorly tolerated, with up to 70{\%} or more of patients noting gastrointestinal issues; this may affect adherence to therapy. In addition, many patients will not respond to oral iron due to their underlying illness. Intravenous iron is being used more frequently to replete iron stores. True anaphylaxis is very rare, but complement-mediated infusion reactions may be seen in up to 1 in every 200 patients. Previous concerns about intravenous iron increasing the risk of infection or cardiovascular disease are unfounded.",
    author = "Thomas Deloughery",
    year = "2019",
    month = "1",
    day = "1",
    doi = "10.1159/000496966",
    language = "English (US)",
    pages = "8--12",
    journal = "Acta Haematologica",
    issn = "0001-5792",
    publisher = "S. Karger AG",

    }

    TY - JOUR

    T1 - Safety of Oral and Intravenous Iron

    AU - Deloughery, Thomas

    PY - 2019/1/1

    Y1 - 2019/1/1

    N2 - As the adverse effects of iron deficiency are better recognized, the use of oral and intravenous iron has increased dramatically. Oral iron is often poorly tolerated, with up to 70% or more of patients noting gastrointestinal issues; this may affect adherence to therapy. In addition, many patients will not respond to oral iron due to their underlying illness. Intravenous iron is being used more frequently to replete iron stores. True anaphylaxis is very rare, but complement-mediated infusion reactions may be seen in up to 1 in every 200 patients. Previous concerns about intravenous iron increasing the risk of infection or cardiovascular disease are unfounded.

    AB - As the adverse effects of iron deficiency are better recognized, the use of oral and intravenous iron has increased dramatically. Oral iron is often poorly tolerated, with up to 70% or more of patients noting gastrointestinal issues; this may affect adherence to therapy. In addition, many patients will not respond to oral iron due to their underlying illness. Intravenous iron is being used more frequently to replete iron stores. True anaphylaxis is very rare, but complement-mediated infusion reactions may be seen in up to 1 in every 200 patients. Previous concerns about intravenous iron increasing the risk of infection or cardiovascular disease are unfounded.

    UR - http://www.scopus.com/inward/record.url?scp=85064347868&partnerID=8YFLogxK

    UR - http://www.scopus.com/inward/citedby.url?scp=85064347868&partnerID=8YFLogxK

    U2 - 10.1159/000496966

    DO - 10.1159/000496966

    M3 - Article

    C2 - 30970354

    AN - SCOPUS:85064347868

    SP - 8

    EP - 12

    JO - Acta Haematologica

    JF - Acta Haematologica

    SN - 0001-5792

    ER -